Results 201 to 210 of about 45,189 (317)

Mandatory Biological/Targeted Synthetic Disease-Modifying Antirheumatic Drugs Dose Reduction on Risk of Serious Infections in Patients with Rheumatoid Arthritis: A Nationwide Nested Case-Control Study. [PDF]

Biomedicines
Chen DY, Lin CH, Chen HH, Chen YM, Tang KT.   +4 more
europepmc   +1 more source

Hepatotoxicity Risk of Isoniazid in Patients with Autoimmune Rheumatic Diseases and Prior Liver Injury Due to Disease-Modifying Antirheumatic Drugs: A Single-Center Experience and Literature Review. [PDF]

J Clin Med
Osorio-Chávez JS, Portilla González V, Ferraz-Amaro I, Castañeda S, Cifrián Martínez JM, Blanco Alonso R.   +5 more
europepmc   +1 more source

Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis [PDF]

, 2010
Haoling H. Weng, Veena K. Ranganath, Dinesh Khanna, Myungshin Oh, Daniel E. Fürst, Grace S. Park, David Elashoff, John T. Sharp, Richard H. Gold, James B. Peter, Harold E. Paulus   +10 more
openalex   +1 more source

From Disease Control to Disease Modification: The Atopic Dermatitis Disease Activity Index

Allergy, Volume 81, Issue 2, Page 577-579, February 2026.
Thomas Bieber, Laura Maintz, Ganesh E. Phad, Marie‐Charlotte Brüggen   +3 more
wiley   +1 more source

Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review. [PDF]

Arthritis Care Res (Hoboken)
Chin A, Terrett A, Kwon M, Whittle S, Hill C.   +4 more
europepmc   +1 more source

Impact of seropositivity and disease-modifying antirheumatic drugs on pulmonary tuberculosis risk in rheumatoid arthritis. [PDF]

ERJ Open Res
Choi H, Eun Y, Han K, Jung JH, Jung W, Kim H, Shin DW, Lee H.   +7 more
europepmc   +1 more source

Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. [PDF]

ACR Open Rheumatol
Mease PJ, Nowak M, Choi J, Lehman T, Sreih A, Ho K, Middaugh N, Ogdie A.   +7 more
europepmc   +1 more source

Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess. [PDF]

Front Pharmacol
Zhang X, Wu X, Luo C, Yang C, Jia N, He J, Chen Q, Wang F.   +7 more
europepmc   +1 more source

Slow-acting antirheumatic drugs.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1982
Rheumatoid arthritis can be controlled by the use of an increasing range of slow-acting drugs and treatments whose mode of action, currently unexplained or lacking a rational basis, may eventually provide a better understanding of the disease.
openaire   +1 more source

POS0161 BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND RISK OF POLYAUTOIMMUNITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

S. Stocklund, F.O. Frimer, Bjarne Magnussen, Kirsten Duch, L. Dreyer, Mette Holland‐Fischer, S. Kristensen   +6 more
openalex   +1 more source